Patents by Inventor Ralph Laufer

Ralph Laufer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of neurodegenerative eye disease using pridopidine
    Patent number: 11738012
    Abstract: The subject invention provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: August 29, 2023
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Hermann Kurt Russ, Michal Geva, Ralph Laufer, Aric Orbach
  • USE OF PRIDOPIDINE FOR TREATING RETT SYNDROME
    Publication number: 20230165849
    Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.
    Type: Application
    Filed: November 19, 2020
    Publication date: June 1, 2023
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal GEVA, Ralph LAUFER, Michael HAYDEN
  • Method of treating amyotrophic lateral sclerosis with pridopidine
    Patent number: 11406625
    Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: August 9, 2022
    Assignee: Prilenia Neurotherapeutics Ltd.
    Inventors: Michal Geva, Ralph Laufer, Michael Hayden, Neta Zach
  • TREATMENT OF NEURODEGENERATIVE EYE DISEASE USING PRIDOPIDINE
    Publication number: 20220062255
    Abstract: This application provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject, pharmaceutical composition and uses and applications thereof.
    Type: Application
    Filed: October 28, 2021
    Publication date: March 3, 2022
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal Geva, Hermann Kurt Russ, Ralph Laufer, Aric Orbach
  • COMPOSITIONS AND METHODS FOR TREATING GM1 GANGLIOSIDOSIS AND OTHER DISORDERS
    Publication number: 20210355506
    Abstract: The disclosure provides gene therapy vectors and methods of use thereof for treating genetic diseases, such as lysosomal storage diseases. For example, the disclosure provides gene therapy vectors and methods for treating GM1 gangliosidosis. The disclosure also provide methods for making the provided gene therapy vectors.
    Type: Application
    Filed: May 13, 2021
    Publication date: November 18, 2021
    Inventors: Michaël HOCQUEMILLER, Karen PIGNET-AIACH, Ralph LAUFER, Sophie OLIVIER, Samantha PARKER
  • USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
    Publication number: 20210106572
    Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.
    Type: Application
    Filed: November 19, 2020
    Publication date: April 15, 2021
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal GEVA, Ralph LAUFER, Michael HAYDEN
  • METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
    Publication number: 20200179355
    Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 11, 2020
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal GEVA, Ralph LAUFER, Michael HAYDEN, Neta ZACH
  • Prodrugs of Chlorokynurenines
    Publication number: 20190308934
    Abstract: The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined herein. Also provided are methods of preparing and using these prodrugs.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Inventors: Ralph Laufer, Gregory R. Ott
  • TREATMENT OF NEURODEGENERATIVE EYE DISEASE USING PRODOPIDINE
    Publication number: 20190046516
    Abstract: The subject invention provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 14, 2019
    Applicant: Teva Pharmaceuticals International GmbH
    Inventors: Hermann Kurt Russ, Michal Geva, Ralph Laufer, Aric Orbach
  • PRODRUGS OF CHLOROKYNURENINES
    Publication number: 20180327351
    Abstract: The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined herein. Also provided are methods of preparing and using these prodrugs.
    Type: Application
    Filed: September 8, 2016
    Publication date: November 15, 2018
    Inventors: Ralph LAUFER, Gregory R. OTT
  • DEUTERATED CHLOROKYNURENINES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
    Publication number: 20180305298
    Abstract: Described are deuterated chlorokynurenines and compositions, and their application as pharmaceuticals for the treatment of disease. Methods of modulating N-methyl-D-aspartate (NMDA) receptor activity, methods of treating disorders, including neuropsychiatric disorders such as depression, epilepsy, schizophrenia, and Huntington's Disease, and use of said deuterated chlorokynurenines are also described.
    Type: Application
    Filed: September 8, 2016
    Publication date: October 25, 2018
    Inventors: Gregory R. OTT, Chengzhi ZHANG, Ralph LAUFER
  • SUBSTITUTED CYCLOHEXANONES
    Publication number: 20180289637
    Abstract: The present disclosure provides compounds of Formula I and/or Formula II, or pharmaceutically acceptable salts thereof: wherein D is deuterium and each deuterium has deuterium enrichment of no less than about 10%, compositions containing these compounds, and methods of using these compounds.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Inventors: Ralph Laufer, Chengzhi Zhang, Yi Wang
  • Tetrahydrocarbazole Inhibitors Of SIRT1 Receptors
    Publication number: 20180127366
    Abstract: Described are deuterium-substituted tetrahydrocarbazole compounds of Formulae I, II, or III which are inhibitors of sirtuin 1 (SIRT1). Also described are pharmaceutical compositions comprising the deuterium-substituted tetrahydrocarbazole compounds, and methods of use thereof.
    Type: Application
    Filed: January 3, 2018
    Publication date: May 10, 2018
    Inventors: Chengzhi Zhang, Ralph Laufer
  • Tetrahydrocarbazole inhibitors of SIRT1 receptors
    Patent number: 9884819
    Abstract: Described are deuterium-substituted tetrahydrocarbazole compounds of Formulae I, II, or III which are inhibitors of sirtuin 1 (SIRT1). Also described are pharmaceutical compositions comprising the deuterium-substituted tetrahydrocarbazole compounds, and methods of use thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 6, 2018
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Chengzhi Zhang, Ralph Laufer
  • Tetrahydrocarbazole Inhibitors Of SIRT1 Receptors
    Publication number: 20170190664
    Abstract: Described are deuterium-substituted tetrahydrocarbazole compounds of Formulae I, II, or III which are inhibitors of sirtuin 1 (SIRT1). Also described are pharmaceutical compositions comprising the deuterium-substituted tetrahydrocarbazole compounds, and methods of use thereof.
    Type: Application
    Filed: January 6, 2017
    Publication date: July 6, 2017
    Inventors: Chengzhi Zhang, Ralph Laufer
  • Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC
    Patent number: 9371295
    Abstract: The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like ?-thalassemia or sickle cell anemia.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: June 21, 2016
    Assignees: IRBM-SCIENCE PARK S.P.A., C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Sergio Altamura, Alberto Bresciani, Giulia Breveglieri, Danilo Fabbrini, Roberto Gambari, Steven Harper, Ralph Laufer, Edith Monteagudo, Emanuela Nizi, Paola Pace, Vincenzo Summa
  • Compounds for use in the treatment of parasitic diseases
    Patent number: 9365541
    Abstract: The present invention relates to compounds useful for treating parasitic diseases, which are infectious diseases caused or transmitted by a parasite. Compounds of the invention are particularly active against the causative pathogens in malaria. Such compounds are selective inhibitors of parasitic histone deacetylase (PfHDAC) and suppress the growth of parasites, such as Plasmodium falciparum, at a lower concentration than the concentration required for the inhibition of the growth of mammalian cells.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 14, 2016
    Assignee: IRBM—SCIENCE PARK S.P.A.
    Inventors: Sergio Altamura, Ilaria Biancofiore, Alberto Bresciani, Federica Ferrigno, Steven Harper, Ralph Laufer, Jesus Maria Ontoria Ontoria, Savina Malancona, Edith Monteagudo, Emanuela Nizi, Maria Vittoria Orsale, Simona Ponzi, Giacomo Paonessa, Vincenzo Summa, Maria Veneziano
  • COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20150299163
    Abstract: The present invention relates to compounds useful for treating parasitic diseases, which are infectious diseases caused or transmitted by a parasite. Compounds of the invention are particularly active against the causative pathogens in malaria. Such compounds are selective inhibitors of parasitic histone deacetylase (PfHDAC) and suppress the growth of parasites, such as Plasmodium falciparum, at a lower concentration than the concentration required for the inhibition of the growth of mammalian cells.
    Type: Application
    Filed: October 30, 2013
    Publication date: October 22, 2015
    Applicants: IRBM - SCIENCE PARK S.P.A., C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Sergio ALTAMURA, Ilaria BIANCOFIORE, Alberto BRESCIANI, Federica FERRIGNO, Steven HARPER, Ralph LAUFER, Jesus Maria ONTORIA ONTORIA, Savina MALANCONA, Edith MONTEAGUDO, Emanuela NIZI, Maria Vittoria ORSALE, Simona PONZI, Giacomo PAONESSA, Vincenzo SUMMA, Maria VENEZIANO
  • COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC
    Publication number: 20150218112
    Abstract: The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like ?-thalassemia or sickle cell anemia.
    Type: Application
    Filed: August 7, 2013
    Publication date: August 6, 2015
    Inventors: Sergio Altamura, Alberto Bresciani, Giulia Breveglieri, Danilo Fabbrini, Roberto Gambari, Steven Harper, Ralph Laufer, Edith Monteagudo, Emanuela Nizi, Paola Pace, Vincenzo Summa
  • Assay for cytochrome P450 isoform 2C9
    Patent number: 7629140
    Abstract: A Rapid And Sensitive Radiometric Assay For Assessing The Activity Of Cytochrome P-450 (CYP) 2C9 And The Potential Of An Analyte To Inhibit CYP2C9 Activity Or Induce CYP2C9 Expression is described. All the steps of the assay, including incubations, product separation, and radioactivity counting are preferably performed in a multiwell format, which can be automated.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: December 8, 2009
    Assignee: Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Ralph Laufer, Annalise Di Marco, Ashok Chaudhary